Your browser doesn't support javascript.
loading
Biallelic loss-of-function in NRAP is a cause of recessive dilated cardiomyopathy.
Koskenvuo, Juha W; Saarinen, Inka; Ahonen, Saija; Tommiska, Johanna; Weckström, Sini; Seppälä, Eija H; Tuupanen, Sari; Kangas-Kontio, Tiia; Schleit, Jennifer; Heliö, Krista; Hathaway, Julie; Gummesson, Anders; Dahlberg, Pia; Ojala, Tiina H; Vepsäläinen, Ville; Kytölä, Ville; Muona, Mikko; Sistonen, Johanna; Salmenperä, Pertteli; Gentile, Massimiliano; Paananen, Jussi; Myllykangas, Samuel; Alastalo, Tero-Pekka; Heliö, Tiina.
Afiliação
  • Koskenvuo JW; Blueprint Genetics, a Quest Diagnostics Company, Espoo, Finland.
  • Saarinen I; Blueprint Genetics, a Quest Diagnostics Company, Espoo, Finland.
  • Ahonen S; Blueprint Genetics, a Quest Diagnostics Company, Espoo, Finland.
  • Tommiska J; Blueprint Genetics, a Quest Diagnostics Company, Espoo, Finland.
  • Weckström S; Heart and Lung Center, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.
  • Seppälä EH; Blueprint Genetics, a Quest Diagnostics Company, Espoo, Finland.
  • Tuupanen S; Blueprint Genetics, a Quest Diagnostics Company, Espoo, Finland.
  • Kangas-Kontio T; Blueprint Genetics, a Quest Diagnostics Company, Espoo, Finland.
  • Schleit J; Blueprint Genetics, a Quest Diagnostics Company, Espoo, Finland.
  • Heliö K; Blueprint Genetics, a Quest Diagnostics Company, Espoo, Finland.
  • Hathaway J; Blueprint Genetics Inc, a Quest Diagnostics Company, Seattle, Washington, United States of America.
  • Gummesson A; Department of Clinical Genetics and Genomics, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • Dahlberg P; Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • Ojala TH; Department of Pediatric Cardiology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
  • Vepsäläinen V; Heart Center, Kuopio University Hospital, Kuopio, Finland.
  • Kytölä V; Blueprint Genetics, a Quest Diagnostics Company, Espoo, Finland.
  • Muona M; Blueprint Genetics, a Quest Diagnostics Company, Espoo, Finland.
  • Sistonen J; Blueprint Genetics, a Quest Diagnostics Company, Espoo, Finland.
  • Salmenperä P; Blueprint Genetics, a Quest Diagnostics Company, Espoo, Finland.
  • Gentile M; Blueprint Genetics, a Quest Diagnostics Company, Espoo, Finland.
  • Paananen J; Blueprint Genetics, a Quest Diagnostics Company, Espoo, Finland.
  • Myllykangas S; Blueprint Genetics, a Quest Diagnostics Company, Espoo, Finland.
  • Alastalo TP; Blueprint Genetics Inc, a Quest Diagnostics Company, Seattle, Washington, United States of America.
  • Heliö T; Heart and Lung Center, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.
PLoS One ; 16(2): e0245681, 2021.
Article em En | MEDLINE | ID: mdl-33534821
ABSTRACT

BACKGROUND:

Familial dilated cardiomyopathy (DCM) is typically a monogenic disorder with dominant inheritance. Although over 40 genes have been linked to DCM, more than half of the patients undergoing comprehensive genetic testing are left without molecular diagnosis. Recently, biallelic protein-truncating variants (PTVs) in the nebulin-related anchoring protein gene (NRAP) were identified in a few patients with sporadic DCM. METHODS AND

RESULTS:

We determined the frequency of rare NRAP variants in a cohort of DCM patients and control patients to further evaluate role of this gene in cardiomyopathies. A retrospective analysis of our internal variant database consisting of 31,639 individuals who underwent genetic testing (either panel or direct exome sequencing) was performed. The DCM group included 577 patients with either a confirmed or suspected DCM diagnosis. A control cohort of 31,062 individuals, including 25,912 individuals with non-cardiac (control group) and 5,150 with non-DCM cardiac indications (Non-DCM cardiac group). Biallelic (n = 6) or two (n = 5) NRAP variants (two PTVs or PTV+missense) were identified in 11 unrelated probands with DCM (1.9%) but none of the controls. None of the 11 probands had an alternative molecular diagnosis. Family member testing supports co-segregation. Biallelic or potentially biallelic NRAP variants were enriched in DCM vs. controls (OR 1052, p<0.0001). Based on the frequency of NRAP PTVs in the gnomAD reference population, and predicting full penetrance, biallelic NRAP variants could explain 0.25%-2.46% of all DCM cases.

CONCLUSION:

Loss-of-function in NRAP is a cause for autosomal recessive dilated cardiomyopathy, supporting its inclusion in comprehensive genetic testing.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Cardiomiopatia Dilatada / Proteínas Musculares Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Child, preschool / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Cardiomiopatia Dilatada / Proteínas Musculares Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Child, preschool / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article